Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: a …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - Wiley Online Library
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …
被引用次数：165 相关文章

Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su, J Guo… - International Journal of …, 2012 - infona.pl
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … Journal of Cancer, 2012 - search.ebscohost.com
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for …

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su, J Guo… - … Journal of Cancer, 2012 - europepmc.org
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for …

Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR: A meta …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - … journal of cancer, 2012 - pubmed.ncbi.nlm.nih.gov
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor-tyrosine kinase inhibitors (EGFR-TKIs), which have been approved for …
[HTML] nih.gov

[HTML][HTML] Epidermal growth factor receptor-tyrosine kinase inhibitor therapy is effective as first-line treatment of advanced non-small-cell lung cancer with mutated EGFR …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su… - Database of Abstracts …, 2012 - ncbi.nlm.nih.gov
The review concluded that epidermal growth factor receptor tyrosine kinase inhibitor
achieved statistically longer progression-free survival, greater overall response rate and …

Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su, J Guo… - International Journal of …, 2012 - cir.nii.ac.jp
抄録< jats: title> Abstract</jats: title>< jats: p> Gefiinib and erlotinib are two similar small
molecules of selective and reversible epidermal growth factor receptor‐tyrosine kinase …

Epidermal growth factor receptor‐tyrosine kinase inhibitor therapy is effective as first‐line treatment of advanced non‐small‐cell lung cancer with mutated EGFR: A …

G Gao, S Ren, A Li, J Xu, Q Xu, C Su, J Guo… - International Journal of …, 2012 - infona.pl
Gefiinib and erlotinib are two similar small molecules of selective and reversible epidermal
growth factor receptor‐tyrosine kinase inhibitors (EGFR‐TKIs), which have been approved …